Fresenius Kabi AG

Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Evonik is discontinuing keto acid manufacturing at its site in Hanau, Germany, by the end of 2025 and will lay off around 260 workers. The company is also looking at divestment and partnership options for its keto and pharma amino acid facilities in France and China, according to an Oct. 11 release. Italian biopharma Chiesi is launching a new €400 million ($433 million) facility in Europe to make monoclonal antibodies, enzymes and other proteins, the company said Monday. The new site will employ 200 staffers by the end of 2025. Indiana-headquartered SpectronRx is expanding to Europe with the radiopharma CDMO earmarking $50 million to build a radiolabeling facility for actinium-225 assets, the company told Endpoints Thursday. Construction in Mol, Belgium, is anticipated to be completed next month, with the site to be operational by the first quarter of 2025. EuroAPI has appointed Olivier Falut as its new chief financial officer. He is replacing Evelyne Nguyen who will stay at the company until the end of October, according to a Wednesday release. The company is in its “year of transition” as it undergoes major restructuring. Texas-based CDMO Matica Biotechnology has signed a new contract with biotech Mongoose Bio, the companies announced Wednesday . Matica Bio will manufacture lentiviruses for Mongoose Bio’s T cell receptor-engineered T cell therapy for cancer. RadioPharma CDMO AtomVie has partnered with Radiopharm Ventures, the company said Tuesday. AtomVie will manufacture the clinical-stage 177 lutetium-conjugated B7-H3-targeting radio antibody, dubbed 177Lu-BetaBart. Perspective Therapeutics’ manufacturing facility in Somerset, NJ, is now operational and has sent its first shipment, the company said Wednesday. The facility manufactures lead-203 and lead-212-labeled radiopharmaceuticals. Cellular Origins and Fresenius Kabi have embarked on a new collaboration for cell therapy manufacturing, the companies announced Wednesday. Cellular Origins will integrate Fresenius Kabi’s cell therapy processing tech into its robotic manufacturing platform, with the aim to manufacture cell therapies on a larger scale. CDMO Cambrex’s storage subsidiary Q1 Scientific has opened a new facility in Durham, NC, to expand storage capacity for pharmaceutical, medical device and life science customers in North America, Cambrex said Wednesday.

The development agreement will see Fresenius Kabi’s cell therapy processing technologies integrated into Cellular Origins’ robotic platform. Credit: Kotin/Shutterstock. Fresenius Kabi and Cellular Origins have announced a partnership to advance the field of cell and gene therapy (CGT) by automating the manufacturing process. Fresenius Kabi’s cell therapy processing technologies will be integrated into Cellular Origins’ Constellation robotic platform. The partnership’s primary objective is to streamline the production of cell therapies at scale, maintaining the use of developers’ preferred tools for processing. This initiative automates the production of advanced therapies, aiming to enhance production efficiency and reduce the risk of human error-induced inconsistencies. The integration process will initially concentrate on Fresenius Kabi’s Cue cell processing system. This system is expected to be fully automated within Constellation, covering aspects from consumable transport to full process operation and data management. See Also: mRNA Covid-19 vaccines may boost cancer immunotherapy effectiveness UNICEF secures one million mpox vaccines for Africa Cellular Origins CEO Dr Edwin Stone stated: “Cellular Origins has developed Constellation to enable fully industrialised manufacture of cell and gene therapies. “Forming strong collaborations is essential to ensuring the industry can implement the transformative power of automation whilst using the tools that are best for the biology and, therefore, for patients. Fresenius Kabi is an industry-leading developer of automated technologies to support the production of cell therapies. “This is why we are excited to be working closely with their team to unlock the power of automation throughout the entire manufacturing process, with the goal of bringing life-saving therapies to patients, faster and more affordably.” The companies will begin their integration efforts with the Cue cell processing system, which is tailored for automated and precise small-volume cell processing. Following success with Cue, the partnership then plans to extend its focus to include Fresenius Kabi’s broader cell therapy technology portfolio, such as the Lovo cell processing system and other products currently under development. In October 2024, Fresenius Kabi won US Food and Drug Administration approval for Otulfi (ustekinumab-aauz), a Stelara biosimilar. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Cell and gene therapies: Pipe dream to pipeline The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Cytiva Thematic By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy

Fresenius, via its operating company Fresenius Kabi, and Cellular Origins, a TTP Company, have entered an agreement to develop integration strategies for Fresenius Kabi’s portfolio of Cell Therapy Technologies within Cellular Origins’ Constellation™ automation platform. The agreement aims to leverage each company’s expertise in cell and gene therapies (CGTs) for digitally and physically integrating Fresenius Kabi’s suite of cell therapy processing technologies within Cellular Origins’ CGT robotic manufacturing platform Constellation™. Initial focus will be on integration of the Cue® Cell Processing System for automated small volume processing. Driving innovation by building momentum in cell and gene therapy, is a further milestone of #FutureFresenius.